Supplement Label Index
Advertisement

Copper

Of 6,796 on-market copper products in the January 2026 DSLD dump, the median declared dose is 1,000 elemental mcg, and 39.9% list unspecified/undisclosed form as the primary form.

6,796
on-market products
1,000 elemental mcg
median dose
39.2%
below RDA
0.3%
above UL
Advertisement

Form share

Of 6,635 products with an identifiable primary form, here is the share held by each form of Copper on the market today.

unspecified/undisclosed form 39.9% Copper Gluconate 21.2% Copper Amino Acid Chelate 20.3% Cupric Oxide 7.2% Copper Citrate 6.4% Copper Sulfate 5.1%
FormQuality tiernShare
unspecified/undisclosed form Unrated 2,646 39.9%
Copper Gluconate Tier 2 1,405 21.2%
Copper Amino Acid Chelate Tier 1 1,347 20.3%
Cupric Oxide Tier 3 478 7.2%
Copper Citrate Tier 2 423 6.4%
Copper Sulfate Tier 2 336 5.1%

Form share over time

Entry-year breakdown of the top forms, 2012–2025.

UnspecifiedCopper GluconateCopper Amino Acid ChelateCupric OxideCopper CitrateCopper Sulfate20122013201420152016201720182019202020212022202320242025

Dose distribution

Deciles of declared dose per serving (elemental mcg), among 6,443 products with a disclosed amount, against the RDA of 900 and UL of 10000.

p10p20p30p40p50p60p70p80p90RDA (900)UL (10000)Fairy-dust
  • 19.1% of products fall below the fairy-dust threshold (400 mcg, 20% of the studied low dose).
  • 1.1% of products don't disclose an amount because Copper is declared inside a proprietary blend.

By dosage form

Tablet or Pill 2,713 Capsule 1,787 Powder 1,105 Other (e.g. tea bag) 656 Softgel Capsule 271 Liquid 197 Unknown 45 Gummy or Jelly 15

By target group

Adult (18 - 50 Years) 4,611 Gluten Free 3,672 Dairy Free 2,348 Vegetarian 1,392 Sugar Free 1,144 Adult Female (18 - 50 Years) 909 Vegan 730 Adult Male (18-50 Years) 693

Top brands

Forms explained

unspecified/undisclosed form Unrated

Label discloses only "Copper" with no salt form.

Copper Gluconate Tier 2

Elemental fraction: 14.0% (Cu(C6H11O7)2, anhydrous, MW 453.87)

Water-soluble, generally regarded as acceptably absorbed, but no dedicated head-to-head human bioavailability RCT was located.

Source: uncertain -- needs review

Cupric Oxide Tier 3

Elemental fraction: 79.9% (CuO, MW 79.55 (stoichiometric only -- actual bioavailable copper delivered is very low))

Provides essentially no bioavailable copper relative to CuSO4 per chick/rat data.

Source: Baker DH. 1999, J Nutr 129:2278-9, PMID 10573563

Copper Sulfate Tier 2

Elemental fraction: 25.4% (CuSO4 x 5H2O, pentahydrate ("blue vitriol", standard USP/commercial form; anhydrous at 0.398 also exists))

Used as the reference/comparator form in most animal copper-bioavailability research; highly soluble but not shown superior to organic/chelated forms.

Source: animal comparator evidence, PMID 7883634, not a human RCT

Copper Citrate Tier 2

Elemental fraction: 35.3% (Real ambiguity between two documented compounds: Cu3(C6H5O7)2 anhydrous (0.335) vs. Cu2(C6H4O7) x 2.5H2O hemipentahydrate, CAS 10402-15-0 (0.353, used here as the CAS-documented commercial solid))

Marketed as a bioavailable organic copper salt; no direct human comparative bioavailability RCT located.

Source: uncertain -- needs review

Copper Amino Acid Chelate Tier 1

Elemental fraction: 30.0% (Cu(C2H4NO2)2, pure 1:2 stoichiometric chelate, MW 211.67 (AAFCO preferred ratio; commercial raw material may be diluted with excess glycine, lowering the actual %))

The specific form used in the one human RCT with a defined copper chelate that demonstrated a measurable physiological effect (raised SOD1/ceruloplasmin).

Source: DiSilvestro RA et al. 2012, Metabolism 61(9):1242-6, PMID 22444781

Reference values

  • RDA (adult): 900 elemental mcg
  • Tolerable Upper Intake Level (adult): 10000 elemental mcg — Based on protection from liver damage
  • Studied clinical dose range: 2000–7800 mcg
  • Low end: DiSilvestro RA et al. 2012, Metabolism 61(9):1242-6, PMID 22444781 -- 2mg Cu/day as copper glycinate x8wk in healthy middle-aged adults; raised erythrocyte SOD1/ceruloplasmin activity, no significant lipid/CRP/homocysteine change. High end: Turnlund JR et al. 2005, Am J Clin Nutr 81(4):822-8, PMID 15817858 -- metabolic-ward study, 7.8mg Cu/day x~4.5 months, showed homeostatic adaptation with signals of concern about sustained high intake.
  • Note: Labels commonly show mg (1mg = 1000mcg); values here kept in mcg to match the ODS RDA/UL unit.
Advertisement